Search
Products
Community
Markets
News
Brokers
More
EN
Get started
Community
/
Ideas
/
MGNX a biotech company gets new "Outperform" LONG
MacroGenics, Inc.
Long
MGNX a biotech company gets new "Outperform" LONG
By AwesomeAvani
Follow
Follow
Updated
Jan 30
1
1
1
Jan 25
MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to
chemotherapy molecules and then heads off looking for cancer cells to which it has a strong
affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about
25% upside. Biotech and healthcare are projected hot sectors this year.
On the 15 minute chart price jumped about 12% in the past week and bounced down toward
the anchored mean VWAP and is well situated for a long entry. the dual TF RSI indicator
shows both lines crossing the 50 level in early bullish momentum off the bounce.
It is continually hitting new past year highs at a great trend angle and is on pace to hit 400% for
an annual return. There is no option play here as the volume is minimal and liquidity is absent.
The all-time high is about $32 so there is plenty of room above the analyst's target over the long
term. Price has moved 12X the S & P YTD certainly a sign of relative strength.
Jan 25
Trade active
finance.yahoo.com/quote/MGNX/news/
Jan 25
Trade active
s3.tradingview.com/snapshots/s/SyjrxDG6.png
Jan 28
Trade active
MGNX up 10% for the week overall. Holding full position. This is expected to be
a long-duration swing trade. When the position is up 10% I will close 20% of the
position.
Jan 30
Trade active
Trade is up 15% - 20% of the position is closed trailing stop loss of 5% on the remaining 80% now a risk-free trade.
biotech
cancerstocks
cancervaccine
LABU
MGNX
Moving Averages
Oscillators
Volume
XBI
AwesomeAvani
Follow
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the
Terms of Use
.